Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.

Bone marrow transplantation·2026

Same author

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.

International journal of molecular sciences·2026

Same author

Unrelated cord blood transplantation and post-transplant cyclophosphamide.

Haematologica·2026

Same author

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Blood advances·2026

Same author

Targeted Screening to Predict <i>Magnusiomyces</i> Infections in Hematopoietic Cell Transplant Recipients: Evidence from an Outbreak Setting.

Journal of fungi (Basel, Switzerland)·2026

Search research articles

Related Experiment Video

Updated: Nov 25, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Second haploidentical stem cell transplantation for primary graft failure.

Sabrina Giammarco¹, Anna Maria Raiola², Carmen Di Grazia²

¹Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy. sabrina_giammarco@libero.it.

Bone Marrow Transplantation

|December 17, 2020

Summary

Patients experiencing primary graft failure after a haploidentical bone marrow transplant can be successfully rescued with a second early haploidentical transplant. This approach, using either the same or a different donor, offers a viable solution for graft failure in haploidentical transplants.

More Related Videos

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Nov 25, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Area of Science:

Hematology
Transplantation Immunology
Oncology

Background:

Primary graft failure (PrGF) is a significant complication following haploidentical (HAPLO) unmanipulated bone marrow transplantation.
Salvage strategies for PrGF are crucial for improving patient outcomes in HAPLO HSCT.

Purpose of the Study:

To evaluate the efficacy of a second HAPLO transplant in patients who experienced PrGF after initial HAPLO HSCT.
To identify factors influencing engraftment and survival after a second HAPLO transplant for PrGF.

Main Methods:

Retrospective analysis of 19 patients who underwent a second HAPLO transplant for PrGF.
Conditioning regimens included total body irradiation (TBI) or fludarabine, busulfan, and thiotepa (TBF).
Graft-versus-host disease (GvHD) prophylaxis involved post-transplant cyclophosphamide (PTCY), cyclosporine, and mycophenolate.

Main Results:

The second HAPLO transplant achieved trilineage recovery in 74% (14/19) of patients.
One-year survival rate was 66% (13/19) after the second HAPLO transplant.
Engraftment was observed in 7/8 patients with and 5/7 patients without donor-specific antibodies (DSA).

Conclusions:

A second early HAPLO transplant is an effective rescue strategy for patients with PrGF after initial HAPLO HSCT.
The use of the same or a different HAPLO donor is feasible for salvage transplantation.
Further research may explore optimal conditioning and GvHD prophylaxis for second HAPLO transplants.